
Mankind Pharma Ltd. (MANKIND) Share Price Falls 4.93% Amid Market Volatility
Updated: 31 Jul 2026 • 9:35 am
Posted by:

Mankind Pharma Ltd. Share Price fell 4.93% to Rs 2,450. Market cap stands at Rs 1,07,071.27 crore.
The Mankind Pharma Ltd. Share Price experienced a significant decline today, falling 4.93% to close at Rs 2,450. This drop comes from a previous close of Rs 2,576.95, marking a notable shift in the company's market position. With a market capitalisation of Rs 1,07,071.27 crore, Mankind Pharma Ltd. remains a major player in the healthcare sector, despite today's setback.
Today's price action saw the stock open at Rs 2,600.1, reaching a high of Rs 2,613.75 and a low of Rs 2,445. The turnover for the day was Rs 2.54 crore, with a total volume of 1,51,304 shares traded across BSE and NSE. This level of activity reflects a heightened interest in the stock, possibly driven by broader market trends rather than company-specific news, as no specific catalyst was identified in the data provided.
Mankind Pharma Ltd. (MANKIND) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,450 |
| Previous Close | Rs 2,576.95 |
| Today's Change | Rs -126.95 (-4.93%) |
| Day Open | Rs 2,600.1 |
| Day High | Rs 2,613.75 |
| Day Low | Rs 2,445 |
| Current Volume (BSE) | 10,369 |
| BSE Traded Volume | 10,369 |
| NSE Traded Volume | 1,40,935 |
| Combined NSE + BSE Volume | 1,51,304 |
| Turnover | Rs 2.54 crore |
| Market Capitalisation | Rs 1,07,071.27 crore |
| Market Cap Category | Large Cap |
Mankind Pharma Ltd. (MANKIND) traded at Rs 2,450. versus the previous close of Rs 2,576.95, a fall of 4.93%. The stock opened at Rs 2,600.1, reached Rs 2,613.75, touched Rs 2,445. Reported volume was 10,369.
Mankind Pharma Ltd. (MANKIND) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,07,071.27 crore |
Mankind Pharma Ltd., with a market capitalisation of Rs 1,07,071.27 crore, is a significant entity in the healthcare sector. The company's valuation metrics, such as P/E and P/B ratios, are crucial for understanding its market positioning.
The healthcare sector, in which Mankind Pharma operates, has a median P/E of 25.77 and a median P/B of 1.93, according to the sector snapshot. These benchmarks provide a context for evaluating the company's valuation relative to its peers. The sector's median ROE and ROCE are 10.74% and 13.24%, respectively, which are useful for assessing the company's profitability and efficiency in using its capital.
While specific financial metrics for Mankind Pharma were not detailed, the sector averages and medians offer a framework for comparison. Investors should consider these benchmarks when evaluating the company's financial health and market performance.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Benchmark Median P/E | 25.77x |
| Benchmark Average P/E | 94.79x |
| Benchmark P/E Range | 3.3x to 3,417.8x |
| Benchmark Median P/B | 1.93x |
| Benchmark Median ROE | 10.74% |
| Benchmark Median ROCE | 13.24% |
| Company Market Capitalisation | Rs 1,07,071.27 crore |
| Benchmark Median Market Cap | Rs 140.91 crore |
Mankind Pharma Ltd. (MANKIND) is classified under sector: Healthcare.
Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Mankind Pharma Ltd. operates within the healthcare sector, a diverse and competitive industry. The sector comprises 198 companies, with a wide range of market capitalisations and financial metrics. The median market capitalisation in the sector is Rs 140.91 crore, significantly lower than Mankind Pharma's Rs 1,07,071.27 crore, indicating its substantial size relative to peers.
The healthcare sector's P/E ratio ranges from 3.3 to 3417.8, with a median of 25.77. This wide range reflects the diversity in company valuations within the sector. Mankind Pharma's valuation metrics, although not specified, would be expected to align with or deviate from these benchmarks, providing insights into its market positioning.
In terms of profitability, the sector's median ROE and ROCE are 10.74% and 13.24%, respectively. These figures serve as benchmarks for assessing Mankind Pharma's financial performance. The company's ability to generate returns on equity and capital employed is crucial for long-term sustainability and growth.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,950.66 | 0 | 0.75 | -2.89 | -0.26 |
| Hikal Ltd. | HIKAL | 2,726.18 | 0 | 2.23 | 15.22 | 16.15 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,700.98 | 39.17 | 7.93 | 28.21 | 26.35 |
| Panacea Biotec Ltd. | PANACEABIO | 2,598.26 | 0 | 8.89 | 0 | 5.36 |
| Beta Drugs Ltd. | BETA | 2,475.7 | 58.88 | 9.32 | 18.65 | 22.17 |
Mankind Pharma Ltd. (MANKIND) has a market capitalisation of Rs 1,07,071.27 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
When comparing Mankind Pharma Ltd. to its peers, several companies in the healthcare sector stand out. For instance, Dishman Carbogen Amcis Ltd. has a market capitalisation of Rs 2,950.66 crore, with a P/B ratio of 0.75 and negative ROE and ROCE, indicating challenges in profitability. In contrast, Kwality Pharmaceuticals Ltd. boasts a P/E of 39.17 and a high ROE of 28.21%, reflecting strong financial performance.
Hikal Ltd. and Beta Drugs Ltd. also present interesting comparisons, with market capitalisations of Rs 2,726.18 crore and Rs 2,475.7 crore, respectively. Both companies have positive ROE and ROCE, suggesting efficient capital use and profitability. These peer comparisons provide a broader context for evaluating Mankind Pharma's market position and financial health.
Why Investors Are Watching Mankind Pharma Ltd.
Investors are closely monitoring Mankind Pharma Ltd. due to its significant market presence and today's notable price decline.
- Price Action: 4.93% decline to Rs 2,450.
- Market Cap: Rs 1,07,071.27 crore, a large-cap entity.
- Sector Context: Operates in the diverse healthcare sector.
- Peer Comparison: Competes with notable healthcare companies.
Moving forward, investors should watch for any sector trends or market dynamics that could influence the company's share price and overall performance.
About Mankind Pharma Ltd.
Mankind Pharma Ltd. is a leading player in the healthcare sector, known for its extensive range of pharmaceutical products. The company operates across various segments, including pharmaceuticals, consumer healthcare, and diagnostics. With a focus on innovation and quality, Mankind Pharma has established a strong presence in the Indian market and continues to expand its footprint globally.
The company's product portfolio includes a wide array of medicines and healthcare products, catering to diverse therapeutic areas. Mankind Pharma's commitment to affordable healthcare solutions has positioned it as a trusted name among healthcare professionals and consumers alike. As the company navigates the competitive landscape, its strategic initiatives and market positioning will be key factors in driving future growth.
Track Mankind Pharma Ltd. Share Price on Univest
Use Mankind Pharma Ltd. (MANKIND) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.
Investors and market enthusiasts can track the Mankind Pharma Ltd. Share Price on Univest for real-time updates. Univest provides comprehensive insights into technical indicators, fundamental ratios, shareholding patterns, and market trends. Stay informed about the latest developments and make data-driven decisions by accessing detailed market analysis and insights on Univest.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What caused the decline in Mankind Pharma Ltd. Share Price today?
Ans. The data confirms a 4.93% decline in Mankind Pharma Ltd. Share Price today, but no specific company-related catalyst was identified. The movement may be influenced by broader market dynamics. The stock moved -4.93% during the session.
How did Mankind Pharma Ltd. perform in today's trading session?
Ans. Mankind Pharma Ltd. Share Price fell 4.93% to Rs 2,450, with a high of Rs 2,613.75 and a low of Rs 2,445. The turnover was Rs 2.54 crore, reflecting active trading.
How does Mankind Pharma Ltd. compare to its peers?
Ans. Mankind Pharma Ltd. competes with peers like Kwality Pharmaceuticals and Hikal Ltd., with varying market caps and financial metrics, offering diverse industry perspectives. Comparable listed companies include Dishman Carbogen Amcis Ltd., Hikal Ltd., Kwality Pharmaceuticals Ltd.
What is the sector context for Mankind Pharma Ltd.?
Ans. Mankind Pharma Ltd. operates in the healthcare sector, which has a median P/E of 25.77 and a median ROE of 10.74%, providing a benchmark for evaluation. The stock belongs to the Healthcare sector.
What are the key financial metrics for the healthcare sector?
Ans. The healthcare sector's median P/E is 25.77, and median ROE is 10.74%. These metrics serve as benchmarks for assessing companies within the sector. The stock belongs to the Healthcare sector.
How can investors track Mankind Pharma Ltd. Share Price?
Ans. Investors can track Mankind Pharma Ltd. Share Price on Univest for real-time updates, technical indicators, and market insights to make informed decisions. The stock moved -4.93% during the session. The intraday range extended from Rs 2,445 to Rs 2,613.75.
Recent Articles

Jai Mata Glass Q1 Results FY27: Net Loss at Rs 0.06 Cr for June 2026 Quarter
31 July 2026

E Factor Experiences Ltd. (EFACTOR-SM) Share Price Rises 8.6% Today
31 July 2026

Go Fashion India Q1 Results FY27: Net Profit at Rs 16 Cr for June 2026 Quarter
31 July 2026

Transpek Industry Ltd. (TRANSPEK) Share Price Rises 8.72% Today
31 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Jai Mata Glass Q1 Results FY27: Net Loss at Rs 0.06 Cr for June 2026 Quarter
E Factor Experiences Ltd. (EFACTOR-SM) Share Price Rises 8.6% Today
Go Fashion India Q1 Results FY27: Net Profit at Rs 16 Cr for June 2026 Quarter
Transpek Industry Ltd. (TRANSPEK) Share Price Rises 8.72% Today
Deep Industries Ltd. (DEEPINDS) Share Price Hits Fresh 52-Week High
Popular this week
Jai Mata Glass Q1 Results FY27: Net Loss at Rs 0.06 Cr for June 2026 Quarter
E Factor Experiences Ltd. (EFACTOR-SM) Share Price Rises 8.6% Today
Go Fashion India Q1 Results FY27: Net Profit at Rs 16 Cr for June 2026 Quarter
Transpek Industry Ltd. (TRANSPEK) Share Price Rises 8.72% Today
Deep Industries Ltd. (DEEPINDS) Share Price Hits Fresh 52-Week High

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





